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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.05.009Objective: Microthrombus formation appears to be one of the major detrimental
factors in lung transplantation from non–heart-beating donors. The purpose of this
study was to evaluate the effects of postmortem heparinization by closed-chest
cardiac massage in a canine model of left single-lung allotransplantation from
non–heart-beating donors.
Methods: Left lung transplantation was performed in 18 weight-matched pairs of
mongrel dogs. Donors were killed with an intravenous injection of potassium
chloride and left at room temperature for 2 hours. The cadaveric donors were
assigned randomly to one of the three groups. In group 1 (n  6), no heparin was
given as a control. In group 2 (n  6), heparin sodium (1000 U/kg) was adminis-
tered intravenously before cardiac arrest. In group 3 (n  6), heparin sodium (1000
U/kg) was administered intravenously 10 minutes after death, then closed-chest
cardiac massage was performed for 2 minutes. After 2 hours of cardiac arrest, donor
lungs were flushed with low-potassium dextran-glucose solution and preserved for
60 minutes. After left lung transplantation, the right pulmonary artery was ligated,
and recipient animals were followed up for 3 hours. Univariate and multivariate
repeated analyses were used for statistics.
Results: Both groups 2 and 3 had significantly better gas exchange and lower
pulmonary vascular resistance than group 1. Changes in thrombin-antithrombin III
complex concentration during the warm ischemia indicated that postmortem hepa-
rinization suppressed clotting activation in the donor.
Conclusions: Postmortem heparinization by cardiac massage is beneficial in lung
transplantation from non–heart beating donors by preventing microthrombus for-
mation.
Agreat disparity between the supply of donor organs and the de-mand of potential recipients has resulted in longer waiting timesand annual increases in deaths on the lung transplant waiting list.As a consequence, efforts have been directed toward the use ofnon–heart-beating donors. Since Steen and colleagues1 describedthe first successful human lung transplantation from an “uncon-
trolled” non–heart-beating donor in 2001, interest in non–heart-beating donors has
seen a recent resurgence.
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TXPrevious experimental studies have shown that a safe
period of ischemia for the lungs at normothermia is less than
2 hours without heparinization,2 but this could be extended
to 4 hours when the lungs were fully heparinized and
ventilated before cardiac arrest.3 However, heparinizing the
donor before death for the purpose of organ donation re-
quires consensus on ethics. With uncontrolled non–heart-
beating donors, heparinization before death is practically
impossible. In this study, we have evaluated the effects of
postmortem heparinization by closed-chest cardiac massage
in a canine model of left single-lung allotransplantation
from non–heart-beating donors.
Material and Methods
Eighteen weight-matched pairs of adult mongrel dogs (7.0-25.0
kg) were used for left single-lung allotransplantation. Donor ani-
mals were premedicated with intramuscular injection of ketamine
hydrochloride (15 mg/kg) and atropine sulfate (0.025 mg/kg).
They were then anesthetized by intravenous injection of thiopental
sodium (7.5 mg/kg) and pancuronium bromide (0.2 mg/kg) and
intubated. The donors were mechanically ventilated with 100%
oxygen and killed with an intravenous injection of potassium
chloride. Cardiac arrest was confirmed by electrocardiography.
The ventilator was stopped and disconnected from the intubated
endotracheal tube. The animals were secured on the table in the
supine position and left at room temperature for 2 hours.
The cadaveric donors were assigned randomly to one of the
three groups. In group 1 (n 6), no heparin was given, for control.
In group 2 (n 6), heparin sodium (1,000 U/kg) was administered
intravenously before cardiac arrest. In group 3 (n  6), heparin
sodium (1,000 U/kg) was administered intravenously 10 minutes
after death, then closed chest cardiac massage was performed for
2 minutes to distribute the heparin around the circulatory system.
Chest compressions were provided 30 times per minute to main-
tain the systolic arterial pressure around 50 to 60 mm Hg.
To measure the degree of clotting activation, the concentration
of the clotting marker thrombin–antithrombin III (TAT) complex
was measured in citrate-anticoagulated plasma by enzyme-linked
immunosorbent assay.4 Serial blood samples were taken from
donors before death and 30, 60, 90, and 120 minutes after death
through a femoral arterial catheter. In group 3, activated coagula-
tion time (ACT) was measured after cardiac massage.
After 2 hours of cardiac arrest, a median sternotomy was
performed. The main pulmonary artery was opened, and the left
atrial appendage was incised. Postmortem thrombus in the pulmo-
nary artery and left atrium was evacuated as much as possible. A
20F catheter was inserted into the main pulmonary artery and
secured. Ventilation was established at a tidal volume of 20 mL/
kg, a respiratory rate of 15 breaths/min, and a positive end-
expiratory pressure of 5 cm H2O. The heart-lung block, ventilated
with 100% oxygen, was perfused with 50-mL/kg low-potassium
dextran-glucose solution5 stored at 4°C from a bag that was hung
50 cm above the chest. Semi-inflated lung block was excised,
submerged in cold saline solution, and stored at 4°C for 60
minutes.
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donors. Anesthesia was maintained with a 50:50 mixture of nitrous
oxide and oxygen and 0.3% to 1.0% halothane. A thermodilution
catheter was placed in the main pulmonary artery from the right
external jugular vein to measure pulmonary arterial pressure, cen-
tral venous pressure, and cardiac output. Aortic pressure was
measured by a femoral artery line. With the animal in the right
lateral decubitus position, a thoracotomy was performed in the left
fifth intercostal space, followed by a left pneumonectomy. The
right pulmonary artery was encircled with 1-0 silk string. A 5F
catheter was inserted into the left atrial appendage to measure left
atrial pressure.
On a back table, the left lung, which was to be used for
implantation, was trimmed from the donor lung block. The donor
right lung was used for histologic study.
Left lung implantation was then performed in the usual fashion.
After transplantation, both lungs were ventilated with a tidal vol-
ume of 20 mL/kg and a positive end-expiratory pressure of 5 cm
H2O at a respiratory rate of 15 breaths/min and an inspired oxygen
concentration of 1.0. The baseline measurement was done. Then
the right pulmonary artery was ligated 15 minutes after reperfusion
so that we could measure the function of the transplanted left lung.
Aortic pressure, pulmonary arterial pressure, central venous pres-
sure, left atrial pressure, and airway pressure were continuously
recorded. Cardiac output and arterial blood gas values were mea-
sured periodically (30 minutes, 60 minutes, 90 minutes, 120 min-
utes, 150 minutes, and 180 minutes after ligation of the right
pulmonary artery).
Animal Care
All dogs received humane care in compliance with the “Principles
of Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” (http://www.nap.edu/catalog/5140.html).
Statistics
Univariate and multivariate repeated analyses were used to deter-
mine whether an overall difference existed in lung function and in
TAT complex data among the three groups during the 3-hour
assessment period. Multiple group comparisons were made with
contrasts. Results are expressed as mean  SEM.
Results
There were no significant differences among the three
groups in donor weight, recipient weight, flushing time,
harvesting time, preparation time, or implantation time. The
flushing times were 269 53 seconds in group 1, 226 52
seconds in group 2, and 213  48 seconds in group 3
(differences not significant). The total ischemic times were
275  15 minutes in group 1, 271  14 minutes in group 2,
and 284  14 minutes in group 3 (differences not signifi-
cant). After left lung allotransplantation, all 18 animals
tolerated the right pulmonary artery ligation and survived
the 3-hour assessment period.
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The results of gas exchange and hemodynamic evaluation
of the recipients during the 3-hour assessment period are
shown in Table 1. Among the various functional indica-
tors, three valuables (PaO2, PaCO2, and pulmonary vascu-
lar resistance) had a significant group effect (P  .001,
P  .01, and P  .03, respectively). Regarding these
TABLE 1. Assessment of lung and cardiac function of rec
Baseline
T
30 min 60 min
PaO2 (mm Hg)
Group 1 513.0 60.8 462.1 63.1 492.2 2
Group 2 612.7 21.7 613.0 22.0* 594.5 2
Group 3 608.2 20.3 549.8 12.1 566.1 1
PaCO2 (mm Hg)
Group 1 47.8 8.4 57.9 5.4 58.4  5
Group 2 38.1 4.2 46.8 4.8 44.6  4
Group 3 35.0 2.7 41.9 3.5* 39.4 4
Mean aortic pressure (mm Hg)
Group 1 115.7 10.4 121.7 12.9 113.0 1
Group 2 111.2 6.0 117.0 7.8 104.3 9
Group 3 103.5 6.4 112.7 12.5 110.0 1
Mean pulmonary arterial pressure (mm Hg)
Group 1 20.5 2.5 41.1 4.0 41.3  4
Group 2 19.1 1.3 37.9 3.4 32.6  3
Group 3 17.8 1.9 33.6 2.9 32.3  2
Mean central venous pressure (mm Hg)
Group 1 5.0 0.5 6.6 0.7 6.3  0
Group 2 4.8 0.6 4.7 0.6 4.9  0
Group 3 4.9 0.4 6.1 1.1 6.5  1
Mean left atrial pressure (mm Hg)
Group 1 6.7 0.6 6.8 1.0 7.3  1
Group 2 7.1 0.8 6.4 0.7 7.0  1
Group 3 7.9 1.2 7.2 1.0 7.5  0
Cardiac output (L/min)
Group 1 1.57 0.49 1.34 0.33 1.17 0
Group 2 1.87 0.70 1.74 0.49 1.56 0
Group 3 2.13 0.4 1.78 0.27 1.97 0
Pulmonary vascular resistance (dyne · s · cm5)
Group 1 1175 446 2887 790 3497 8
Group 2 788 218 1812 312 1762 3
Group 3 396 49 1316 218* 1153 2
Mean airway pressure (mm Hg)
Group 1 6.0 0.4 6.3 0.3 6.6  0
Group 2 6.3 0.3 6.1 0.2 6.4  0
Group 3 5.6 0.3 5.8 0.3 6.0  0
All values are given as mean  SEM.
*P  .05 versus group 1.
†P  .01 versus group 1.
‡P  .001 versus group 1.three valuables, all three comparisons (group 1 vs group
The Journal of Thoraci2, group 1 vs group 3, and group 2 vs group 3) for each
time point were performed. PaO2 was significantly better
in groups 2 and 3 than in group 1. PaCO2 was significantly
lower in groups 2 and 3 than in group 1. Pulmonary
vascular resistance was significantly lower in groups 2
and 3 than in group 1. There were no significant differ-
ences between groups 2 and 3 in these three functional
ts
fter ligation of right pulmonary artery
P value
(overall
group
effect)90 min 120 min 150 min 180 min
.0001
418.3 45.9 313.3 59.9 245.0 68.9 193.5 64.7
574.7 15.1† 580.3 29.8‡ 575.3 21.8‡ 556.3 19.6‡
558.5 21.9† 580.0 16.1‡ 583.6 14.5‡ 589.1 17.3‡
.01
59.0  5.7 59.4 6.6 63.3 7.3 65.3  6.3
43.2  3.0* 44.5 3.0* 43.4 3.4† 41.6 3.2‡
37.4 3.7‡ 36.6 3.4‡ 37.9 3.7‡ 37.2 3.8‡
.98
116.0 11.7 108.3 14.4 108.2 13.4 107.2 15.5
113.7 6.9 109.7 10.4 107.8 11.4 102.8 13.1
108.7 13.3 117.3 12.3 118.5 12.6 113.0 11.9
.13
38.7  2.4 37.7 1.6 38.6 1.9 36.3  1.8
33.0  3.1 32.0 3.5 32.7 3.0 31.6  3.3
29.8  2.4 30.7 2.4 32.5 1.8 31.6  2.2
.27
6.3  0.9 6.4  0.8 6.0  0.6 6.8  0.4
4.6  0.8 4.3  0.8 4.3  0.6 4.5  0.8
5.8  1.0 5.8  0.9 5.8  0.8 5.7  0.7
.55
7.3  0.9 6.3  0.8 7.5  1.0 7.6  1.1
5.6  0.8 5.7  0.9 5.2  0.7 4.9  0.7
7.0  1.2 7.2  1.4 7.3  1.6 7.4  1.8
.52
1.24 0.30 1.11 0.28 1.21 0.28 1.08 0.26
1.50 0.44 1.38 0.36 1.34 0.30 1.50 0.47
1.83 0.30 1.72 0.25 1.74 0.24 1.72 0.25
.03
2589 500 2935 552 2495 426 2588 405
1779 260 1898 372 1931 347 1882 353
1133 210† 1208 230† 1293 223* 1262 255*
.68
6.7  0.4 6.9  0.3 6.8  0.4 7.0  0.5
6.8  0.3 6.8  0.3 6.8  0.3 6.8  0.4
6.6  0.3 6.6  0.4 6.7  0.4 6.6  0.5ipien
ime a
1.8
7.5†
1.4*
.9
.0
.0†
4.5
.2
2.9
.0
.1
.8
.7
.7
.6
.2
.6
.8
.34
.54
.34
52
27*
04†
.5
.2
.3indicators. There were no significant group effects in
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TXmean aortic pressure, mean pulmonary arterial pressure,
mean central venous pressure, mean left atrial pressure,
cardiac output, and mean airway pressure.
Macroscopic and Microscopic Findings
In group 1, the donor lung surface looked patchy macro-
scopically after pulmonary flush, indicating inhomogeneous
perfusion (Figure 1, A). The poorly perfused area was seen
in the dorsal side of the donor lung. In group 2, the whole
donor lung surface looked uniformly perfused (Figure 1, B).
The patchy area was less observed in group 3 than in group
1 (Figure 1, C).
Histologic studies of samples of lung parenchyma ob-
tained after pulmonary flushing demonstrated many residual
blood cells or blood clots in group 1 (Figure 2, A). These
blood cells or blood clots were less observed in groups 2
and 3 (Figure 2, B and C).
TAT Complex
The changes in TAT complex concentration in each group
are shown in Figure 3. The TAT complex concentration in
group 1 increased significantly after death, and it was sig-
nificantly higher than in groups 2 and 3 after 60 minutes of
warm ischemic time (P  .001). On the other hand, con-
centrations were stable in both groups 2 and 3 after death,
and there was no significant difference between the two
Figure 1. Macroscopic findings of donor lung after
solution in each group. A, Donor left lung in group 1
perfusion. Poorly perfused area was seen on dorsal
uniformly perfused. C, Donor left lung in group 3. Patcgroups.
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In group 3, ACT measured after cardiac massage exceeded
1500 seconds in all 6 cadaveric donors.
Discussion
In response to the growing demand for lung transplantation,
efforts have been directed toward the use of living-do-
nors,6,7 marginal donors,8 and non–heart-beating donors.1
Ischemic injury is minimized in the case of heart-beating
donors because cessation of circulation occurs simulta-
neously with perfusion of preservation solution and rapid
cooling. Use of a non–heart-beating donor imposes isch-
emic injury caused by prolonged circulatory arrest in warm
temperature.
Several investigators2,3,9 have conducted examinations
of the lung’s tolerance of warm ischemia. It has been proved
that lung cells remain viable by metabolizing the oxygen in
the alveoli for a certain period even at warm temperatures
without circulation.10 A safe period for the lungs at normo-
thermia is less than 2 hours without heparinization.2 Ulicny
and colleagues3 demonstrated that the acceptable warm
ischemic time could be extended to 4 hours when the lungs
were fully heparinized before cardiac arrest and kept ven-
tilated after death. A number of strategies have been devel-
oped in an attempt to reduce warm ischemic injury: oxygen
radical scavengers,11 topical cooling,12 leukocyte deple-
tion,13 inhaled nitric oxide,14 fibrinolytic drugs,15 and ret-
onary flushing with low-potassium dextran-glucose
g surface looked patchy, indicating inhomogeneous
. B, Donor left lung in group 2. Lung surface looked
rea was less observed in group 3 than in group 1.pulm
. Lun
siderograde pulmonary flush.16
uary 2005
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ditions, two classes of non–heart-beating donors, controlled
and uncontrolled, have been distinguished.17 Controlled
non–heart-beating donors undergo circulatory arrest after
planned withdrawal of life support with a retrieval team
standing by. Heparin is usually administered before cardiac
arrest to prevent microthrombus formation. Successful
transplants from controlled non–heart beating donors have
been reported for the kidney,18 pancreas,19 liver,19,20 and
lung.19 However, heparinizing the donor before death for
the purpose of organ donation requires consensus on the
ethics, because it could hasten death in donors with brain
injury. In fact, the practice is strictly restricted in Japan.
The first successful human lung transplantation from an
uncontrolled non–heart beating donor was reported by
Steen and colleagues1 in 2001, and it is gathering much
attention. The donor was a 54-year-old man who had an
acute myocardial infarction. After unsuccessful resuscita-
tion, the patient was declared dead. Heparin was given into
a central venous catheter 10 minutes after declaration of
death, followed by 20 chest compressions. With an in-
trapleural cooling technique, the right lung was transplanted
successfully into a 54-year-old woman with chronic ob-
structive pulmonary disease.
Postmortem heparinization by closed-chest cardiac mas-
sage is potentially problematic because it could cause pul-
monary contusion and could deliver microthrombi and toxic
cytokines to the lungs from venous blood. We hypothesized
that postmortem heparinization by cardiac massage would
Figure 2. Histologic studies of samples of donor right
Group 2. C, Group 3. Many residual blood cells or clots
1. Blood cells or blood clots were less observed in grimprove overall lung function by preventing microthrombus
The Journal of Thoraciformation in lung transplantation from non–heart-beating
donors.
In this study, heparin was given intravenously 10 min-
utes after cardiac arrest in group 3. Equivalent pulmonary
functions were obtained in groups 2 (premortem hepariniza-
tion) and 3 (postmortem heparinization), whereas group 1
(no heparinization) showed worse pulmonary function. It
Figure 3. Changes in TAT complex concentration in each group.
TAT complex concentration in group 1 significantly increased
after death and was significantly higher than in groups 2 and 3
after 60 minutes of warm ischemic time. Concentrations were
stable in both groups 2 and 3 after death, and there was no
significant difference between these groups. Triple asterisks
indicate P < .001 versus group 1.
after pulmonary flushing in each group. A, Group 1. B,
observed in capillary, as indicated by arrows in group
2 and 3.lung
werewas clearly shown that postmortem heparinization by
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TXclosed-chest cardiac massage improved gas exchange and
lowered pulmonary vascular resistance (Table 1). Preven-
tion of microthrombus formation by postmortem hepa-
rinization was confirmed macroscopically (Figure 1, A-C)
and microscopically (Figure 2, A-C). Prolonged ACT in
group 3 demonstrated that systemic heparinization could be
achieved by closed-chest cardiac massage for 2 minutes.
Significant inhibition of the clotting system was also dem-
onstrated by the changes in TAT complex in group 3 (Fig-
ure 3).
Postmortem heparinization by closed-chest compression
can be achieved easily by anyone, anywhere, without spe-
cial equipment. It should be also emphasized that no skin
incision is required. It therefore can be readily applied to
uncontrolled non–heart-beating donors, including those
dead on arrival at the hospital. However, it would be essen-
tial to administer heparin shortly after cardiac arrest. Further
study is needed to determine the optimal time for postmor-
tem heparinization in lung transplantation from non–heart-
beating donors.
We acknowledge the expert technical assistance of Tetsuo
Kawakami and the statistical advice of Richard B. Schuessler,
PhD.
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